专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

WO2009065551A1 METHOD OF ASSESSING COLORECTAL CANCER FROM A STOOL SAMPLE BY USE OF THE MARKER COMBINATION CALPROTECTIN AND HEMOGLOBIN/HAPTOGLOBIN COMPLEX 审中-公开
标题翻译：通过使用标记卡培他滨和HEMOGLOBIN / HAPTOGLOBIN复合物从STOOL样品评估颜色性癌症的方法
公开(公告)号：WO2009065551A1
公开(公告)日：2009-05-28
申请号：PCT/EP2008/009733
申请日：2008-11-18
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA-ROCHE AG , KARL, Johann , GARCZAREK, Ursula , WILD, Norbert
发明人： KARL, Johann , GARCZAREK, Ursula , WILD, Norbert
IPC分类号： G01N33/574
CPC分类号： G01N33/57419 , G01N33/721 , G01N2333/4727 , G01N2333/805
摘要： The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.
摘要翻译：本发明涉及一种协助评估结肠直肠癌的方法。该方法特别用于评估体外存在或不存在结肠直肠癌。该方法例如通过分析生物化学标记来实施，包括在粪便样品中测量血红蛋白/触珠蛋白复合物和钙卫蛋白的浓度，并将确定的浓度与不存在或存在结肠直肠癌相关联。为了进一步改善基于本发明方法的结肠直肠癌的评估，可以在粪便样品中与血红蛋白/触珠蛋白复合物和钙卫蛋白一起测定一种或多种另外的标记物的水平，并与结肠直肠癌的存在或不存在相关。本发明还涉及包含血红蛋白/触珠蛋白复合物和钙卫蛋白的标记物在早期诊断结肠直肠癌中的用途，并且其教导了用于实施本发明方法的试剂盒。

22. 发明申请

WO2007134779A1 USE OF PROTEIN S100A 12 AS A MARKER FOR COLORECTAL CANCER 审中-公开
标题翻译：使用蛋白S100A 12作为彩色癌的标记
公开(公告)号：WO2007134779A1
公开(公告)日：2007-11-29
申请号：PCT/EP2007/004378
申请日：2007-05-16
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , WILD, Norbert , ANDRES, Herbert , GARCZAREK, Ursula , GEISTANGER, Andrea , HAGMANN, Marie-Luise , KARL, Johann , KRAUSE, Friedemann , PFEFFER, Michael , ROLLINGER, Wolfgang , TACKE, Michael , THIEROLF, Michael
发明人： WILD, Norbert , ANDRES, Herbert , GARCZAREK, Ursula , GEISTANGER, Andrea , HAGMANN, Marie-Luise , KARL, Johann , KRAUSE, Friedemann , PFEFFER, Michael , ROLLINGER, Wolfgang , TACKE, Michael , THIEROLF, Michael
IPC分类号： G01N33/53 , C12Q1/68
CPC分类号： G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A 12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A 12 in said sample. Measurement of S100A 12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质S100A12在诊断结肠直肠癌中的应用。本发明涉及一种通过测量所述样品中的S100A 12从粪便样品中诊断结直肠癌的方法。 S100A12的测定例如可以用于结肠直肠癌的早期检测或诊断。

23. 发明申请

WO2005040809A1 USE OF PROTEIN HNRNP-F AS A MARKER FOR BREAST CANCER 审中-公开
标题翻译：使用蛋白质HNRNP-F作为乳腺癌标记物
公开(公告)号：WO2005040809A1
公开(公告)日：2005-05-06
申请号：PCT/EP2004/011657
申请日：2004-10-15
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , PESTLIN, Gabriele , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , WILD, Norbert , ZOLG, Werner
发明人： PESTLIN, Gabriele , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , WILD, Norbert , ZOLG, Werner
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N33/57496 , G01N33/6875
摘要： The present invention relates to the diagnosis of breast cancer. It discloses the use of heterogeneous nuclear ribonucleoprotein F (hnRNP-F) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring hnRNP-F in said sample. Measurement of hnRNP-F can, e.g., be used in the early detection or diagnosis of breast cancer.
摘要翻译：本发明涉及乳腺癌的诊断。它公开了异源核核糖核蛋白F（hnRNP-F）在乳腺癌诊断中的应用。本发明涉及一种通过测量所述样品中的hnRNP-F从个体得到的来自液体样品的乳腺癌诊断方法。 hnRNP-F的测定可以例如用于乳腺癌的早期检测或诊断。

24. 发明申请

WO2005040805A1 USE OF PROTEIN MASP AS A MARKER FOR BREAST CANCER 审中-公开
标题翻译：使用蛋白质大豆作为乳腺癌标志物
公开(公告)号：WO2005040805A1
公开(公告)日：2005-05-06
申请号：PCT/EP2004/011596
申请日：2004-10-15
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , PESTLIN, Gabriele , ANDRES, Herbert , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , ZOLG, Werner
发明人： PESTLIN, Gabriele , ANDRES, Herbert , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , ZOLG, Werner
IPC分类号： G01N33/574
CPC分类号： G01N33/57415
摘要： The present invention relates to the diagnosis of breast cancer. It discloses the use of protein MASP in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring MASP in said sample. Measurement of MASP can, e.g., be used in the early detection or diagnosis of breast cancer.
摘要翻译：本发明涉及乳腺癌的诊断。它公开了蛋白质MASP在乳腺癌诊断中的应用。本发明涉及一种通过测量所述样品中的MASP从个体获得的来自液体样品的乳腺癌诊断方法。 MASP的测量可以例如用于乳腺癌的早期检测或诊断。

25. 发明申请

WO2005015233A1 USE OF PROTEIN SPERMIDINE SYNTHASE (SPEE) AS A MARKER FOR COLORECTAL CANCER 审中-公开
标题翻译：蛋白质合成酶（SPEE）作为色素标记物的使用
公开(公告)号：WO2005015233A1
公开(公告)日：2005-02-17
申请号：PCT/EP2004/008930
申请日：2004-08-10
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , TACKE, Michael , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , PALME, Stefan , ROESSLER, Markus , ROLLINGER, Wolfgang , ZOLG, Werner
发明人： TACKE, Michael , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , PALME, Stefan , ROESSLER, Markus , ROLLINGER, Wolfgang , ZOLG, Werner
IPC分类号： G01N33/574
CPC分类号： G01N33/57419 , G01N2333/91171
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein SPEE (protein spermidine synthase) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring SPEE in said sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质SPEE（蛋白质亚精胺合酶）在结肠直肠癌诊断中的应用。它涉及一种通过测量所述样品中的SPEE从个体得到的粪便样品中诊断结肠直肠癌的方法。 SPEE的测量可以例如用于结肠直肠癌的早期检测或诊断。

26. 发明申请

WO2005015230A1 USE OF PROTEIN PSA3 AS A MARKER FOR COLORECTAL CANCER 审中-公开
标题翻译：使用蛋白PSA3作为彩色癌症的标记
公开(公告)号：WO2005015230A1
公开(公告)日：2005-02-17
申请号：PCT/EP2004/008870
申请日：2004-08-06
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , TACKE, Michael , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , PALME, Stefan , ROESSLER, Markus , ROLLINGER, Wolfgang , ZOLG, Werner
发明人： TACKE, Michael , BERNDT, Peter , HAGMANN, Marie-Luise , KARL, Johann , LANGEN, Hanno , PALME, Stefan , ROESSLER, Markus , ROLLINGER, Wolfgang , ZOLG, Werner
IPC分类号： G01N33/574
CPC分类号： G01N33/57419 , G01N2333/95
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein proteasome subunit alpha 3 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring PSA3 in said sample. Measurement of PSA3 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质组蛋白酶亚基α3在结直肠癌诊断中的应用。本发明涉及通过测量所述样品中的PSA 3从粪便样品中诊断结直肠癌的方法。 PSA3的测定可以例如用于结肠直肠癌的早期检测或诊断。

27. 发明申请

WO2019012019A1 NEW BINDING AGENT AND ASSAY FOR PIVKA 审中-公开
公开(公告)号：WO2019012019A1
公开(公告)日：2019-01-17
申请号：PCT/EP2018/068871
申请日：2018-07-12
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： ECKERT, Bernhard , GERG, Michael , KARL, Johann , KAUFMANN, Martin , RIEDLINGER, Julia , SWIATEK-DE LANGE, Magdalena , HILLRINGHAUS, Lars , HIRZEL, Klaus , LISY, Marcus-Rene
IPC分类号： C07K16/36 , C07K16/30 , C07K16/40
摘要： The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art.

28. 发明申请

WO2018024905A1 CIRCULATING ESM-1 (ENDOCAN) IN THE ASSESSMENT OF ATRIAL FIBRILLATION AND STROKE 审中-公开
标题翻译：循环ESM-1（ENDOCAN）评估心房颤动和脑卒中
公开(公告)号：WO2018024905A1
公开(公告)日：2018-02-08
申请号：PCT/EP2017/069864
申请日：2017-08-04
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： KARL, Johann , KASTNER, Peter , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZIEGLER, André , DIETRICH, Manuel , SCHOTTEN, Uli , ROLNY, Vinzent
IPC分类号： G01N33/68
摘要： The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure. Methods for predicting the risk of stroke are also disclosed, such as cardioembolic stroke and stroke associated with atrial fibrillation.
摘要翻译：本发明涉及评估受试者中心房纤颤的方法，所述方法包括以下步骤：确定来自受试者的样品中ESM-1的量，并比较ESM- 1至参考量，由此评估心房纤颤。此外，本发明涉及用于诊断与心力衰竭相关的心脏衰竭和/或至少一种结构或功能异常的方法。还公开了预测中风风险的方法，例如心房栓塞性中风和与心房颤动相关的中风。

29. 发明申请

WO2017153336A1 DETECTION OF ANTI-P53 ANTIBODIES 审中-公开
标题翻译：检测抗P53抗体
公开(公告)号：WO2017153336A1
公开(公告)日：2017-09-14
申请号：PCT/EP2017/055190
申请日：2017-03-06
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： ANDRES, Herbert , KARL, Johann , KUNERT, Ursula , MORGENSTERN, David , MEISSLER, Nina , NIESSNER, Marion , SWIATEK-DE LANGE, Magdalena
IPC分类号： G01N33/574 , C07K14/47
CPC分类号： G01N33/564 , C07K16/46 , G01N33/574 , G01N33/5748 , G01N33/57496
摘要： The disclosure relates to an in vitro method for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
摘要翻译：本公开涉及用于检测样品中p53抗体（抗p53抗体）的体外方法，所述方法包括：将要分析的样品与p53捕获抗原和p53 由此形成包含p53捕获抗原，抗p53抗体和p53检测抗原的复合物，分离由未结合的检测抗原形成的复合物并测量通过其中包含的检测抗原获得的复合物，包含在样品中的p53抗体。

30. 发明申请

WO2017148854A1 IGFBP-7 AS A MARKER IN PREECLAMPSIA 审中-公开
标题翻译： IGFBP-7作为前列腺炎的标志物
公开(公告)号：WO2017148854A1
公开(公告)日：2017-09-08
申请号：PCT/EP2017/054484
申请日：2017-02-27
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： HUND, Martin , KAISER, Edelgard Anna , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , KARL, Johann
IPC分类号： G01N33/68 , G06F19/10
CPC分类号： G01N33/689 , G01N33/6893 , G01N2333/4703 , G01N2333/4745 , G01N2800/368 , G01N2800/52 , G01N2800/60 , G16B99/00
摘要： The present invention relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The preeclampsia-related condition can be eclampsia, HELLP syndrome or proteinuria. Said method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also encompassed by the present invention are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present invention further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Optionally, sFlt-1, Endoglin, PIGF are determined. Finally, the present invention relates to a device adapted to carry out the method of the present invention.
摘要翻译：本发明涉及用于诊断怀孕受试者中先兆子痫或先兆子痫相关病症的方法。先兆子痫相关病症可以是子痫，HELLP综合征或蛋白尿。所述方法基于对来自受试者的样品中生物标志物IGFBP-7（胰岛素样生长因子结合蛋白7）的量的测量以及将测量量与参比进行比较。本发明还包括用于评估先兆子痫或先兆子痫相关病症的严重程度的方法以及用于监测怀孕受试者中先兆子痫或先兆子痫相关病症的方法。本发明进一步涉及生物标志物IGFBP-7或特异性结合来自怀孕受试者的样品中的IGFBP-7的试剂用于诊断，监测或评估先兆子痫或先兆子痫相关病症的严重程度。任选地，确定sFlt-1，内皮糖蛋白，PIGF。最后，本发明涉及一种适于执行本发明方法的装置。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式